EyePoint Pharmaceuticals

EYPT

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Weak

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

EyePoint Pharmaceuticals is a small biotech company focused on treating serious eye diseases. Its main product is DURAVYU (vorolanib), a sustained-release implant designed to treat wet age-related macular degeneration (wet AMD) and diabetic macular edema — conditions that can cause blindness. The company's customers are ophthalmologists and the patients they treat, primarily older adults in the United States.

EyePoint earns revenue through drug sales and licensing agreements, though it is still in an early commercial stage and currently spends far more than it earns — as shown by its deeply negative operating margin. The company operates mainly in the US and relies on its proprietary Durasert drug-delivery platform, which slowly releases medicine inside the eye over months, as its core competitive advantage. The key growth driver is the commercial rollout of DURAVYU, but the main risk is that the wet AMD market is already dominated by well-established injectable therapies, making it difficult and expensive to win market share.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-90.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-28.2% YoY

YoY Growth Rate

Earnings declining

Insider Activity

16.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~4 months

$180M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

EyePoint Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-19207.1%

Losing money on operations — -19207.1%

Return on the money invested

ROCE

-190.5%

Weak — -190.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-94.6%

Shrinking sales (-94.6% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-12650.6%

Burning cash (-12650.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial